SG74074A1 - Use of inhibitors of the sodium-hydrogen exchanger for the production of a pharmaceutical for the treatment of disorders which are caused by protozoa - Google Patents

Use of inhibitors of the sodium-hydrogen exchanger for the production of a pharmaceutical for the treatment of disorders which are caused by protozoa

Info

Publication number
SG74074A1
SG74074A1 SG1998003335A SG1998003335A SG74074A1 SG 74074 A1 SG74074 A1 SG 74074A1 SG 1998003335 A SG1998003335 A SG 1998003335A SG 1998003335 A SG1998003335 A SG 1998003335A SG 74074 A1 SG74074 A1 SG 74074A1
Authority
SG
Singapore
Prior art keywords
protozoa
disorders
inhibitors
pharmaceutical
sodium
Prior art date
Application number
SG1998003335A
Other languages
English (en)
Inventor
Hans Jochen Lang
Michael Lanzer
Jochen Wiesner
Cecilia Sanchez
Stefan Wuensch
Original Assignee
Hoechst Marion Roussel De Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Marion Roussel De Gmbh filed Critical Hoechst Marion Roussel De Gmbh
Publication of SG74074A1 publication Critical patent/SG74074A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
SG1998003335A 1997-08-28 1998-08-27 Use of inhibitors of the sodium-hydrogen exchanger for the production of a pharmaceutical for the treatment of disorders which are caused by protozoa SG74074A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19737463A DE19737463A1 (de) 1997-08-28 1997-08-28 Verwendung von Inhibitoren des Natrium-Wasserstoff-Austauschers zur Herstellung eines Arzneimittels zur Behandlung von Erkrankungen, die durch Protozoen verursacht werden

Publications (1)

Publication Number Publication Date
SG74074A1 true SG74074A1 (en) 2000-07-18

Family

ID=7840411

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1998003335A SG74074A1 (en) 1997-08-28 1998-08-27 Use of inhibitors of the sodium-hydrogen exchanger for the production of a pharmaceutical for the treatment of disorders which are caused by protozoa

Country Status (26)

Country Link
US (1) US6114393A (zh)
EP (1) EP0901788A3 (zh)
JP (1) JPH11171792A (zh)
KR (1) KR100567144B1 (zh)
CN (1) CN1244322C (zh)
AR (1) AR013949A1 (zh)
AU (1) AU738599B2 (zh)
BR (1) BR9803243A (zh)
CA (1) CA2246407A1 (zh)
CZ (1) CZ296815B6 (zh)
DE (1) DE19737463A1 (zh)
HK (1) HK1018589A1 (zh)
HR (1) HRP980468A2 (zh)
HU (1) HU225583B1 (zh)
ID (1) ID20794A (zh)
IL (1) IL125946A0 (zh)
MY (1) MY137406A (zh)
NO (1) NO320368B1 (zh)
NZ (1) NZ331566A (zh)
PL (1) PL191267B1 (zh)
RU (1) RU2225726C2 (zh)
SG (1) SG74074A1 (zh)
SK (1) SK285457B6 (zh)
TR (1) TR199801669A2 (zh)
TW (1) TW592690B (zh)
ZA (1) ZA987781B (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9224739D0 (en) * 1992-11-26 1993-01-13 Wellcome Found Medicaments
MXPA02006328A (es) * 1999-12-23 2002-12-13 Pfizer Prod Inc Forma de dosificacion de farmacos accionada por un hidrogel.
US7375138B2 (en) * 2002-05-18 2008-05-20 Sanofi-Aventis Deutschland Gmbh Pentafluorosulfanylbenzoylguanidines, processes for their preparation, their use as medicaments or diagnostic aids, and medicaments comprising them
FR2840302B1 (fr) * 2002-06-03 2004-07-16 Aventis Pharma Sa Derives d'isoindolones, procede de preparation et intermediaire de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
US6878748B2 (en) 2002-06-13 2005-04-12 Aventis Pharma Deutschland Gmbh Fluorinated cycloalkyl-derivatized benzoylguanidines, process for their preparation, their uses as medicament, and medicament containing them
CA3069046A1 (en) * 2017-07-04 2019-01-10 Sanofi Ethynyl compounds, their preparation and their therapeutic use for the treatment of malaria

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1336871A (en) * 1970-01-02 1973-11-14 Wellcome Found Method for preparing biologically active substituted amidines
US4032655A (en) * 1974-05-15 1977-06-28 Bayer Aktiengesellschaft Phenylguanidines useful as anthelmintic agents
US4088780A (en) * 1974-05-15 1978-05-09 Bayer Aktiengesellschaft Substituted phenylguanidines and processes for their preparation and use
US4544670A (en) * 1982-08-24 1985-10-01 William H. Rorer, Inc. Method of treating coccidiosis with acyl guanidines
DE3929582A1 (de) * 1989-09-06 1991-03-07 Hoechst Ag Benzoylguanidine, verfahren zu ihrer herstellung, ihre verwendung als medikament sowie sie enthaltendes medikament
IN172842B (zh) * 1990-05-17 1993-12-11 Boots Pharmaceuticals Limited
ATE158589T1 (de) * 1991-11-22 1997-10-15 Yeda Res & Dev Nicht-peptidische surrogate der arg-gly-asp sequenz und entsprechende pharmazeutische zusammensetzungen
CZ284456B6 (cs) * 1992-02-15 1998-12-16 Hoechst Aktiengesellschaft Aminosubstituované benzoylguanidiny, způsob jejich přípravy, jejich použití jako léčiv a léčivo, které je obsahuje
GB9224739D0 (en) * 1992-11-26 1993-01-13 Wellcome Found Medicaments
DE4318658A1 (de) * 1993-06-04 1994-12-08 Hoechst Ag Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE4318756A1 (de) * 1993-06-05 1994-12-08 Hoechst Ag Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19502644A1 (de) * 1995-01-28 1996-08-01 Merck Patent Gmbh 4-Amino-benzoylguanidin-Derivate
FR2734263B1 (fr) * 1995-05-17 1997-06-20 Fournier Ind & Sante Analogues de la 15-deoxyspergualine, leur procede de preparation et leur utilisation en therapeutique
ES2216049T3 (es) * 1995-06-07 2004-10-16 Genaera Corporation Compuestos de aminosterol utiles como inhibidores del intercambiador de sodio/protones (nhe), metodos y composiciones farmaceuticas que emplean dichos inhibidores y procesos para evaluar la eficacia inhibidora de nhe de dichos compuestos.
DE19542306A1 (de) * 1995-11-14 1997-05-15 Hoechst Ag Sulfonylamino-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament

Also Published As

Publication number Publication date
RU2225726C2 (ru) 2004-03-20
PL191267B1 (pl) 2006-04-28
CZ272998A3 (cs) 1999-03-17
NO983943D0 (no) 1998-08-27
CZ296815B6 (cs) 2006-06-14
EP0901788A2 (de) 1999-03-17
SK117498A3 (en) 1999-03-12
PL328265A1 (en) 1999-03-01
IL125946A0 (en) 1999-04-11
TR199801669A3 (tr) 1999-03-22
KR19990023905A (ko) 1999-03-25
HK1018589A1 (en) 1999-12-30
HUP9801925A3 (en) 2004-11-29
NO320368B1 (no) 2005-11-28
JPH11171792A (ja) 1999-06-29
CN1209994A (zh) 1999-03-10
NZ331566A (en) 2001-03-30
DE19737463A1 (de) 1999-03-04
HU9801925D0 (en) 1998-10-28
CA2246407A1 (en) 1999-02-28
HU225583B1 (en) 2007-03-28
HRP980468A2 (en) 1999-06-30
EP0901788A3 (de) 2004-01-02
TR199801669A2 (xx) 1999-03-22
AU738599B2 (en) 2001-09-20
SK285457B6 (sk) 2007-02-01
ZA987781B (en) 1999-05-27
ID20794A (id) 1999-03-04
KR100567144B1 (ko) 2006-11-30
TW592690B (en) 2004-06-21
AR013949A1 (es) 2001-01-31
US6114393A (en) 2000-09-05
AU8189498A (en) 1999-03-11
HUP9801925A1 (hu) 2000-02-28
MY137406A (en) 2009-01-30
BR9803243A (pt) 2000-03-21
CN1244322C (zh) 2006-03-08
NO983943L (no) 1999-03-01

Similar Documents

Publication Publication Date Title
HU0003863D0 (en) Alpha-sulfonylamino hidroxamic acid inhibitors of matrix metalloproteinases for the treatment of peripheral or central nervous system disorders
HK1046132A1 (en) Acyl derivatives which treat vla-4 related disorders
ID28529A (id) Vinileter heterosiklik untuk gangguan neurologi
NO20004688L (no) Terapi ved østrogenassosierte lidelser
PL351134A1 (en) Compositions for treatment of disorders of the oesophagus
PL373626A1 (en) Treatment for central nervous system disorders
AU8187701A (en) Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders
ZA9810218B (en) Isoquinoline derivatives for use against cns disorders
HUP0004613A3 (en) Process for the production of aromatic amines
SG74074A1 (en) Use of inhibitors of the sodium-hydrogen exchanger for the production of a pharmaceutical for the treatment of disorders which are caused by protozoa
PT1294710E (pt) Derivados de indole uteis para o tratamento de disturbios do snc
IS1919B (is) Bensamíð til að meðhöndla taugahrörnunarsjúkdóma
FR2777560B1 (fr) Procede de purification de polyamines aromatiques
CZ20011872A3 (cs) Isonipekotamidy pro léčbu onemocnění zprostředkovaných integriny
IL126068A0 (en) The use of inhibitors of the sodium-hydrogen exchanger for the production of a medicament for decreasing undesired effects of substances on the heart
IL141031A0 (en) New pharmaceutical uses for nos inhibitors
IL126276A0 (en) The use of an inhibitor of the na+/H+ exchanger for the production of a medicament for the treatment or prophylaxis of disorders of the central nervous system
HK1040933A1 (zh) N-取代的氮雜二環烷衍生物在治療中樞神經系統疾病中的應用
ZA988729B (en) The use of an inhibitor of the Na/H+ exchanger for the production of a medicament for the treatment or prophylaxis of disorders of the central nervous system
FR2770214B1 (fr) Procede de preparation d'un benzamide halogene
EP1178814A4 (en) METHOD OF IDENTIFYING THERAPEUTIC COMPOUNDS FOR THE TREATMENT OF HEPATIC DISORDERS
FR2761685B1 (fr) Procede de preparation des dinitroanilines 4-substituees
FR2765576B1 (fr) Procede de preparation des dinitroanilines 4-substituees
FR2802924B1 (fr) Procede de preparation des 6-halogeno-2-chloroquinoxalines
FR2760011B1 (fr) Procede de preparation de 3-chloromethyl-3-alkyloxethane